Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Home / Firms / Pabst Patent Group, LLP
Last updated: May 29, 2026

Pabst Patent Group, LLP

103 pending office actions • 53 clients • 97 examiners • 57 art units • 0 of 103 (0%) have an AI response strategy ready • 64 patents granted in the last 365 days

Portfolio Summary

103
Total Pending OAs
63
Non-Final OAs
40
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 103 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

57
Overdue
1
Due this week
31
Due this month
9
Due in next 60 days
5
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 103 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (57)Due ≤ 7 days (1)Due ≤ 30 days (31)Due ≤ 60 days (9)Due later (5)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (2%)
70
Medium (68%)
14
Easy (14%)
17
Unknown (17%)

Rejection Statute Mix

BucketCases
§101 only2 (2%)
§103 only64 (62%)
§102 only6 (6%)
§112 only14 (14%)
No statute on record17 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

94
Life Sciences
91% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
2
Semiconductors
2% of docket
7
Mechanical / Eng
7% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

1,030 h
Manual time on pending OAs
206 h
Time saved (low, 20%)
360 h
Time saved (mid, 35%)
9.0 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SINGH, ANOOP KUMAR 3 42.8% +67.6%
WANG, RUIXUE 2 57.6% +23.2%
GIAMMONA, FRANCESCA FILIPPA 2 35.7% +53.3%
DARPOLOR, JOSEPHINE KEBBEH 2 61.5% +41.7%
SVEIVEN, MICHAEL CAMERON 2 35.3% +38.1%
TCHERKASSKAYA, OLGA V 1 55.4% +46.6%
ROBERTS, ANNA L 1 54.7% +43.4%
COHEN, MICHAEL P 1 58.5% +27.6%
XIE, XIAOZHEN 1 55.9% +65.9%
HA, JULIE 1 75.6% +44.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
16975351 EZETIMIBE METABOLITE AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) SVEIVEN, MICHAEL CAMERON 5d overdue
17294196 ORAL WASH FOR ORAL FLUID COLLECTION AND ANALYSIS AND METHODS OF USE THEREOF CRAIG, KAILA ANGELIQUE 15d

Interview Candidates (16)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18783166 TRANSMEMBRANE SENSOR TO EVALUATE NEUROMUSCULAR FUNCTION ROBERTS, ANNA L 111d overdue
17777011 SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES SVEIVEN, MICHAEL CAMERON 80d overdue
17584547 CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS SINGH, ANOOP KUMAR 59d overdue
19107055 GADUSOL-CONTAINING SUNSCREEN FORMULATIONS TCHERKASSKAYA, OLGA V 58d overdue
17426057 METHODS FOR PREDICTING A VERY LOW BIRTH WEIGHT GIAMMONA, FRANCESCA FILIPPA 38d overdue
17048297 IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER WANG, RUIXUE 31d overdue
18653312 COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS XIE, XIAOZHEN 26d overdue
17259766 COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE SINGH, ANOOP KUMAR 8d overdue

Client Portfolio (53 clients)

Client (Assignee)Pending OAs
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 13
THE UNIVERSITY OF HONG KONG 10
University of Arizona 7
Ohio State University 6
Yale University 5
IMPERIAL COLLEGE INNOVATIONS LIMITED 5
Augusta University 4
Hong Kong Quantum AI Lab 3
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2
REGENTS OF THE UNIVERSITY OF MINNESOTA 2
D&D Pharmatech 2
VERSITECH LIMITED 2
Fusion Pharmaceuticals 2
Arcaea 1
Powell Mansfield, Inc. 1
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 1
Carbice 1
RAMOT AT TEL-AVIV UNIVERSITY LTD. 1
University of California 1
THE HOSPITAL AUTHORITY 1
Xiamen Tungsten 1
UNIVERSITY OF KANSAS 1
EPFL 1
The University of Maine System Board of Trustees 1
Harvard University 1
Credentis 1
Hillhurst 1
Nugift Medical LLC 1
THE GENERAL HOSPITAL CORPORATION 1
Chinese University of Hong Kong 1
University of Bari Aldo Moro 1
Centre for Virology, Vaccinology and Therapeutics 1
Rab Diagnostics AS 1
Centre for Oncology and Immunology 1
SALK INSTITUTE FOR BIOLOGICAL STUDIES 1
MJS Solutions 1
PONTIFICIA UNIVERSIDAD JAVERIANA 1
NANYANG TECHNOLOGICAL UNIVERSITY 1
H. Lee Moffitt Cancer and Research Institute, Inc. 1
Golden Dragon Rare-Earth Innovation Technology (Xiamen) Co., Ltd. 1
MuniRem Environmental 1
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 1
Centre for Probe Development and Commercialization 1
Guangzhou iGene Biotechnology Co., Ltd. 1
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE 1
The University of Kansas 1
Decima Diagnostics, LLC 1
Fulgent Pharma 1
GEORGIA TECH RESEARCH CORPORATION 1
MIT 1
VCell Therapeutics, Inc. 1
Dartmouth College 1
Exzymatic Deinking Technologies, L.L.C. 1

Top Art Units

Art UnitApps
16425
16544
16384
16324
16534
16723
37743
16783
16753
16363

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19107055 GADUSOL-CONTAINING SUNSCREEN FORMULATIONS Arcaea, LLC TCHERKASSKAYA, OLGA V 1615 §103 Non-Final OA 58d overdue Pending Feb 27, 2025
18783166 TRANSMEMBRANE SENSOR TO EVALUATE NEUROMUSCULAR FUNCTION Powell Mansfield, Inc. ROBERTS, ANNA L 3791 §103 Non-Final OA 111d overdue Pending Jul 24, 2024
18674209 POLY(AMINE-CO-ESTER) POLYMERS AND POLYPLEXES WITH MODIFIED END GROUPS AND METHODS OF USE THEREOF Yale University COHEN, MICHAEL P 1612 Other Non-Final OA 16d Pending May 24, 2024
18653312 COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS H. Lee Moffitt Cancer Center and Research Institute, Inc. XIE, XIAOZHEN 1674 §112 Non-Final OA 26d overdue Pending May 02, 2024
18652429 TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute HA, JULIE 1654 §103 Non-Final OA 14d Pending May 01, 2024
18622465 CARBON NANOTUBE-BASED THERMAL INTERFACE MATERIALS AND METHODS OF MAKING AND USING THEREOF Carbice Corporation ROJOHN III, CLAIRE E 3763 §103 Non-Final OA 36d overdue Pending Mar 29, 2024
18605474 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE Ramot AT Tel-Aviv University Ltd. NEAGU, IRINA 1629 Other Non-Final OA 4d overdue Pending Mar 14, 2024
18564498 BIOENGINEERED DERMAL PAPILLA AND HAIR FOLLICLES AND RELATED PRODUCTS, METHODS AND APPLICATIONS The University of Hong Kong MATALKAH, FATIMAH KHALAF 1638 §103 Non-Final OA 13d Pending Nov 27, 2023
18563314 DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF Hong Kong Quantum AI Lab Limited DULKA, JOHN P 2817 §112 Non-Final OA 17d overdue Pending Nov 21, 2023
18503100 COMPOSITIONS AND METHODS FOR MAKING PARASYMPATHETIC NEURONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. JACKSON III, WALTER 1638 §103 Non-Final OA 31d overdue Pending Nov 06, 2023
18500774 ENGINEERED EXOSOMES TO DETECT AND DEPLETE PRO-TUMORIGENIC MACROPHAGES Augusta University Research Institute, Inc. NICOL, ALEXANDER W 1634 §103 Non-Final OA 13d Pending Nov 02, 2023
18490443 USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING The Regents of the University of California PHILIPOSE, HANNAH SARAH 1631 §103 Non-Final OA 2d overdue Pending Oct 19, 2023
18375697 COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS Ohio State Innovation Foundation COUGHLIN, MATTHEW P 1626 §103 Non-Final OA 29d overdue Pending Oct 02, 2023
18478247 ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS H. Lee Moffitt Cancer Center and Research Institute, Inc. BELYAVSKYI, MICHAIL A 1644 Other Final Rejection 91d overdue Pending Sep 29, 2023
18473956 COMPOSITIONS FOR CORONAVIRUS DETECTION AND METHODS OF MAKING AND USING THEROF The Hospital Authority WANG, RUIXUE 1672 §112 Non-Final OA 12d Pending Sep 25, 2023
18549950 CHIPS AND METHODS Imperial College Innovations Ltd. KIDWELL, KAITLYN ELIZABETH 2877 §103 Final Rejection 85d overdue Pending Sep 11, 2023
18549770 METHODS, SYSTEMS, AND DEVICES FOR GENERATING DEFINED FIBER CONSTRUCTS Arizona Board of Regents LEYSON, JOSEPH S 1744 §103 Non-Final OA 29d Pending Sep 08, 2023
18548687 Combination Therapy to Treat Temperature Sensitive Mutant Tumors H. Lee Moffitt Cancer Center and Research Institute, Inc. FLANAGAN, BEVERLY MEINDL 3794 §103 Final Rejection 43d Pending Sep 01, 2023
18547748 METHODS FOR TREATING CD83-EXPRESSING CANCER Regents Of The University Of Minnesota GODDARD, LAURA B 1642 Other Non-Final OA 9d overdue Pending Aug 24, 2023
18546408 DOUBLE-SHELL NEODYMIUM-IRON-BORON MAGNET AND PREPARATION METHOD THEREFOR Fujian Golden Dragon Rare-Earth Co., Ltd. WU, JENNY R 1733 §103 Non-Final OA 78d overdue Pending Aug 14, 2023
18546302 CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES H. Lee Moffitt Cancer Center and Research Institute, Inc. GUSTILO, ESTELLA M 1646 §103 Non-Final OA 24d overdue Pending Aug 14, 2023
18357065 COMPOSITIONS AND METHODS FOR DETECTING TRYPANOSOMA CRUZI INFECTION UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. CHEONG, CHEOM-GIL 1645 §102 Non-Final OA 3d overdue Pending Jul 21, 2023
18356886 EXTRACELLULAR VESICLE PROTEOMIC BIOMARKER PANEL FOR OVARIAN CANCER SCREENING AND THE EARLY DETECTION OF DISEASE UNIVERSITY OF KANSAS BELLAH, JEFFREY LAWRENCE 1683 §112 Non-Final OA 9d Pending Jul 21, 2023
18262287 BI-SPECIFIC CAR T CCELLS FOR B CELL MALIGNANCIES H. Lee Moffitt Cancer Center and Research Institute, Inc. METCALF, MATTHEW CURRAN 1647 Other Non-Final OA 28d Pending Jul 20, 2023
18353717 DINUCLEAR PLATINUM COMPLEXES FOR OLED APPLICATION Hong Kong Quantum AI Lab Limited DEKARSKE, MADELINE MCGUIRE 1622 §103 Non-Final OA 4d overdue Pending Jul 17, 2023
18352040 COMPOSITIONS AND METHODS TARGETING S100A10 FOR THE TREATMENT AND DIAGNOSIS OF LIVER CANCER The University of Hong Kong CASH, KAILEY ELIZABETH 1683 §103 Non-Final OA 22d overdue Pending Jul 13, 2023
18269114 A METHOD ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE WOLLSCHLAGER, JEFFREY MICHAEL 1742 §103 Non-Final OA 11d overdue Pending Jun 22, 2023
18335922 COMPOSITIONS CONTAINING AMINO ACIDS AS AN ADMIXTURE FOR CEMENT-BASED MATERIALS The University of Maine System Board of Trustees GREEN, ANTHONY J 1731 §103 Non-Final OA 25d overdue Pending Jun 15, 2023
18039130 BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO D&D Pharmatech Inc. COFFA, SERGIO 1658 Other Non-Final OA 33d Pending May 26, 2023
18253891 COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY Arizona Board of Regents VISHNYAKOVA, ELENA VLADIMIROVNA 1691 §103 Non-Final OA 19d Pending May 22, 2023
18314688 IMMUNOTHERAPY OF SKIN CANCER USING MPLA-LOADED HPG NANOPARTICLES Yale University RONEY, CELESTE A 1612 Other Final Rejection 22d Pending May 09, 2023
18312492 FORMULATIONS AND MEDICAL DEVICES FOR MINIMALLY-INVASIVE DEEP TISSUE APPLICATIONS President and Fellows of Harvard College WHITE, KIA XIONG 3774 §103 Non-Final OA 9d Pending May 04, 2023
18251078 COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES Arizona Board of Regents BEANE, RANDALL L 1654 §102 Non-Final OA 55d Pending Apr 28, 2023
18249648 ACCELERATING TOOTH REMINERALISATION AND BONE REGENERATION WITH SELF-ASSEMBLING PEPTIDES AND AMORPHOUS CALCIUM PHOSHATE Credentis AG HELLMAN, KRISTINA M 1654 §102 Non-Final OA 84d Pending Apr 19, 2023
18248285 METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS Imperial College Innovations Limited GIAMMONA, FRANCESCA FILIPPA 1681 §103 Non-Final OA 14d Pending Apr 07, 2023
18245217 COMPOSITIONS AND METHODS FOR INHIBITING TREM-1 Augusta University Research Institute, Inc. JOHNSON, CHRISTOPHER LINDSAY 1691 §103 Non-Final OA 77d overdue Pending Mar 14, 2023
18179069 ENTERAL CARBON MONOXIDE FOR THE PREVENTION AND TREATMENT OF OCULAR DISEASES Hillhurst Biopharmaceuticals, Inc. STEINKE, SEAN JAMES 1619 §102 Final Rejection 34d Pending Mar 06, 2023
18178282 PIG XENOTRANSPLANTS INTO HUMANS WITHOUT CHRONIC IMMUNOSUPPRESSION Nugift Medical LLC SINGH, ANOOP KUMAR 1632 §112 Non-Final OA 63d Pending Mar 03, 2023
18169695 HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING The General Hospital Corporation STEVENS, MARK V 1613 §103 Non-Final OA 14d Pending Feb 15, 2023
18005016 FORMATE-INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF Imperial College Innovations Ltd. RYAN, DOUGLAS CHARLES 1635 §112 Non-Final OA 12d Pending Jan 10, 2023
18003922 DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS H. Lee Moffitt Cancer Center and Research Institute, Inc. JUEDES, AMY E 1644 Other Non-Final OA 66d overdue Pending Dec 30, 2022
18012468 A MECHANOMYOGRAPHY APPARATUS AND ASSOCIATED METHODS Imperial College Innovations Limited CERIONI, DANIEL LEE 3791 §103 Final Rejection 1d overdue Pending Dec 22, 2022
18063604 COMPOSITIONS AND METHODS FOR IMPROVED MESENCHYMAL STEM CELL THERAPY The Chinese University of Hong Kong WHITE, DAWANNA SHAR-DAY 1627 §103 Final Rejection 18d overdue Pending Dec 08, 2022
18000491 COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION The University of Hong Kong NGUYEN, NGOC-ANH THI 1615 §103 Final Rejection 295d overdue Pending Dec 01, 2022
18000425 SSTR-2 Binding Chimeric Antigen Receptors UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO DARPOLOR, JOSEPHINE KEBBEH 1642 §103 Final Rejection 9d Pending Dec 01, 2022
18000312 Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells H. Lee Moffitt Cancer Center and Research Institute, Inc. HOPKINS, SAMANTHA LAKE 1641 §103 Non-Final OA 20d Pending Nov 30, 2022
18058169 VIRAL NUCLEIC ACID MOLECULES, AND COMPOSITIONS AND METHODS OF USE THEREOF Centre For Virology, Vaccinology And Therapeutics Limited KINSEY WHITE, NICOLE ERIN 1672 §103 Non-Final OA 23d overdue Pending Nov 22, 2022
18057632 d10 METAL CARBENE COMPLEXES FOR OLED APPLICATIONS Hong Kong Quantum AI Lab Limited KERSHNER, DYLAN CLAY 1786 §103 Non-Final OA 36d Pending Nov 21, 2022
17998790 CANNABIDIOL AS A THERAPEUTIC MODALITY FOR COVID-19 Augusta University Research Institute, Inc. RAMACHANDRAN, UMAMAHESWARI 1627 §103 Final Rejection 23d Pending Nov 14, 2022
17996427 COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA Augusta University Research Institute, Inc. SEITZ, ANTHONY JOSEPH 1629 Other Non-Final OA 81d overdue Pending Oct 17, 2022
18046619 DIAGNOSIS AND TREATMENT OF CANCER Rab Diagnostics AS YAO, LEI 1642 §103 Final Rejection 23d Pending Oct 14, 2022
17906279 DESIGNER EXTRACELLULAR VESICLES FOR TREATING EXCITOTOXICITY Ohio State Innovation Foundation TICHY, JENNIFER M.H. 1653 §103 Final Rejection 29d Pending Sep 14, 2022
17930591 COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF VERSITECH LIMITED HOLLAND, PAUL J 1656 §103 Final Rejection 23d Pending Sep 08, 2022
17821411 COMPOSITIONS AND METHODS FOR DETECTING SARS-CoV-2 The University of Hong Kong BARRERA, IMMACULADA 1671 §103 Final Rejection 4d overdue Pending Aug 22, 2022
17871412 COSMECEUTICAL COMPOSITION Ohio State Innovation Foundation PRAGANI, RAJAN 1614 Other Final Rejection 104d overdue Pending Jul 22, 2022
17759271 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CD83 AND INTERLEUKIN 6 RECEPTOR H. Lee Moffitt Cancer Center and Research Institute, Inc. WESTON, ALYSSA G 1633 §102 Final Rejection 20d Pending Jul 21, 2022
17756386 CAR T CELLS WITH ENHANCED METABOLIC FITNESS H. Lee Moffitt Cancer Center and Research Institute, Inc. BERTOGLIO, VALARIE E 1632 §103 Final Rejection 111d overdue Pending May 24, 2022
17756138 AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE H. Lee Moffitt Cancer Center and Research Institute, Inc. HILL, KEVIN KAI 1638 §112 Final Rejection 44d overdue Pending May 18, 2022
17777011 SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES Arizona Board of Regents SVEIVEN, MICHAEL CAMERON 1678 Other Non-Final OA 80d overdue Pending May 13, 2022
17735271 COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER Centre For Oncology And Immunology Limited MCANANY, JOHN D 1625 §103 Final Rejection 12d Pending May 03, 2022
17734826 COMPOSITE FILAMENT FOR 3D PRINTING OF RESORBABLE BONE SCAFFOLDS Arizona Board of Regents BAHENA, CHRISTIE L. 3774 §103 Final Rejection 28d Pending May 02, 2022
17729584 SURGERY DEVICE WITH PATIENT-SPECIFIC FIBULA MALLEOLUS CAP The University of Hong Kong HU, ANN M 3774 §103 Final Rejection 72d Pending Apr 26, 2022
17769524 METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN Salk Institute For Biological Studies KIM, TAEYOON 1631 §103 Final Rejection 147d overdue Pending Apr 15, 2022
17769642 COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES Yale University PATTERSON, SARAH COOPER 1675 §112 Non-Final OA 11d overdue Pending Apr 15, 2022
17762931 METHOD FOR ISOLATING EXTRACELLULAR VESICLES Imperial College Innovations Limited ZINGARELLI, SANDRA 1653 §103 Non-Final OA 34d Pending Mar 23, 2022
17694312 TOPICAL DRUG DELIVERY DEVICES AND METHODS OF USE Mjs Solutions, LLC GHALI, ISIS A D 1611 §103 Final Rejection 3d overdue Pending Mar 14, 2022
17641516 NANOPARTICLES FOR SELECTIVE TISSUE OR CELLULAR UPTAKE Yale University LAZARO, DOMINIC 1611 §103 Final Rejection 30d overdue Pending Mar 09, 2022
17640756 COMPOSITIONS AND METHODS FOR COGNITIVE PROTECTION OF POLLINATORS AGAINST PESTICIDES Pontificia Universidad Javeriana GALSTER, SAMUEL LEONARD 1693 §102 Non-Final OA 23d Pending Mar 04, 2022
17635119 ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS H. Lee Moffitt Cancer Center and Research Institute, Inc. LUNDE, GRACE HENRY 1641 Other Non-Final OA 184d overdue Pending Feb 14, 2022
17635111 CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES Regents Of The University Of Minnesota BERHANE, SELAM 1675 Other Non-Final OA 39d Pending Feb 14, 2022
17669059 THREE-DIMENSIONAL POROUS HYBRID SCAFFOLD AND MANUFACTURE THEREOF Nanyang Technological University MARTIN, PAUL C 1653 §103 Non-Final OA 78d Pending Feb 10, 2022
17584547 CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS H. Lee Moffitt Cancer Center and Research Institute, Inc. SINGH, ANOOP KUMAR 1632 §112 Non-Final OA 59d overdue Pending Jan 26, 2022
17583549 Composition for and Method of Improving Tissue Performance Ohio State Innovation Foundation REYNOLDS, FRED H 1658 §103 Non-Final OA 72d overdue Pending Jan 25, 2022
17628920 COMBINATION THERAPY FOR TREATING RAS-MUTANT CANCERS H. Lee Moffitt Cancer Center and Research Institute, Inc. DARPOLOR, JOSEPHINE KEBBEH 1642 §103 Non-Final OA 26d Pending Jan 21, 2022
17626954 R-Fe-B SINTERED MAGNET AND GRAIN BOUNDARY DIFFUSION TREATMENT METHOD THEREOF Golden Dragon Rare-Earth Innovation Technology (Xiamen) Co., Ltd. POLLOCK, AUSTIN M 1738 §103 Final Rejection 54d Pending Jan 13, 2022
17625665 COMPOSITIONS AND METHODS FOR CLEARING TISSUE The University of Hong Kong BARRON, SEAN C 1653 §103 Non-Final OA 11d overdue Pending Jan 07, 2022
17622048 NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS Ohio State Innovation Foundation HUDSON, AMY ROSE 1636 §103 Non-Final OA 29d Pending Dec 22, 2021
17557920 ZERO-VALENT METAL AND BLACK CARBON FRAMEWORK AND METHOD OF USING SAME MuniRem Environmental, LLC MAYES, MELVIN C 1759 §112 Non-Final OA 28d overdue Pending Dec 21, 2021
17615504 PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME D&D Pharmatech Inc. JARRELL, NOBLE E 1699 §112 Non-Final OA 56d Pending Nov 30, 2021
17614934 THERAPEUTIC B-CELLS ENGINEERED TO EXPRESS BISPECIFIC T CELL ENGAGER ANTIBODIES H. Lee Moffitt Cancer Center and Research Institute, Inc. SPENCE, JENNIFER SUZANNE 1633 §103 Final Rejection 128d overdue Pending Nov 29, 2021
17610892 SENSORS AND METHODS USING ELECTROCHEMILUMINESCENCE OF METAL NANOCLUSTERS Georgia State University Research Foundation, Inc. DICKINSON, PAUL W 1618 §103 Non-Final OA 12d Pending Nov 12, 2021
17517039 PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF Centre For Probe Development And Commercialization DONOHUE, SEAN R 1618 Other Non-Final OA 15d Pending Nov 02, 2021
17296115 DNA REFERENCE STANDARD AND USE THEREOF Guangzhou Igene Biotechnology Co., Ltd. GOLDBERG, JEANINE ANNE 1682 §103 Final Rejection 28d overdue Pending Oct 29, 2021
17600922 CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING VERSITECH LIMITED MARTINEZ, TARA L 1654 §103 Final Rejection 70d Pending Oct 01, 2021
17426057 METHODS FOR PREDICTING A VERY LOW BIRTH WEIGHT Imperial College Of Science, Technology And Medicine GIAMMONA, FRANCESCA FILIPPA 1681 §103 Non-Final OA 38d overdue Pending Jul 27, 2021
17416172 PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES The University of Kansas VANHORN, ABIGAIL LOUISE 1636 §103 Non-Final OA 17d overdue Pending Jun 18, 2021
17337358 RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY Fusion Pharmaceuticals Inc. VALLE, ERNESTO 1623 Other Final Rejection 141d overdue Pending Jun 02, 2021
17294196 ORAL WASH FOR ORAL FLUID COLLECTION AND ANALYSIS AND METHODS OF USE THEREOF Decima Diagnostics, LLC CRAIG, KAILA ANGELIQUE 1618 §101 Final Rejection 15d Pending May 14, 2021
17289590 COMPOSITIONS AND METHODS FOR MODULATING EGG DEVELOPMENT IN MOSQUITOES Arizona Board of Regents DACE DENITO, ALEXANDRA GERALDINE 1636 §112 Final Rejection 8d Pending Apr 28, 2021
17281411 TLR9-TARGETED THERAPEUTICS Fulgent Pharma LLC TRAN, CHRISTINA L 1637 §112 Final Rejection 19d overdue Pending Mar 30, 2021
17278189 IMPROVED HIGH-THROUGHPUT COMBINATORIAL GENETIC MODIFICATION SYSTEM AND OPTIMIZED CAS9 ENZYME VARIANTS The University of Hong Kong LIPPOLIS, ALEXANDRA ROSE 1637 §103 Final Rejection 16d overdue Pending Mar 19, 2021
17272124 COMPOSITIONS AND METHODS OF USING CELL-PENETRATING ANTIBODIES IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS Yale University ESSEX, LAURA ANN 1675 §103 Final Rejection 45d overdue Pending Feb 26, 2021
17269968 TREATMENT OF FLAVIVIRUS INFECTIONS IN HUMANS USING MUS MUSCULUS RESISTANT 2'-5' OLIGOADENYLATE SYNTHETASE 1B Georgia Tech Research Corporation DUNSTON, JENNIFER ANN 1637 §103 Non-Final OA 53d overdue Pending Feb 19, 2021
17265756 COMPOSITIONS AND METHODS FOR DETECTION AND IMAGING OF AMYLOID FIBRILS, AMYLOID PLAQUES, RNA, AND NUCLEOLI The University of Hong Kong NGUYEN, NAM P 1678 Other Non-Final OA 43d overdue Pending Feb 03, 2021
17259766 COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE Ohio State Innovation Foundation SINGH, ANOOP KUMAR 1632 §103 Final Rejection 8d overdue Pending Jan 12, 2021
17048297 IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER The University of Hong Kong WANG, RUIXUE 1672 §103 Final Rejection 31d overdue Pending Oct 16, 2020
17033050 CELL-BASED CANCER VACCINES AND CANCER THERAPIES Massachusetts Institute Of Technology REDDIG, PETER J 1646 §103 Non-Final OA 124d overdue Pending Sep 25, 2020
17011239 VACCINE FOR TREATMENT OF CANCER AND METHOD OF MAKING BY STRESS REPROGRAMMING VCell Therapeutics, Inc. SULLIVAN, DENNIS JOHN 1642 §103 Final Rejection 85d overdue Pending Sep 03, 2020
16975351 EZETIMIBE METABOLITE AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) Arizona Board of Regents SVEIVEN, MICHAEL CAMERON 1678 §101 Non-Final OA 5d overdue Pending Aug 24, 2020
16985432 CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS The Trustees of Dartmouth College ROGERS, ERIC JASON 1638 §112 Final Rejection 29d Pending Aug 05, 2020
16768319 TRANSGENIC RICE PLANTS OVEREXPRESSING ACYL-COA-BINDING PROTEIN2 SHOW ENHANCED GRAIN SIZE The University of Hong Kong BOGGS, RUSSELL T 1663 §103 Final Rejection 4d overdue Pending May 29, 2020
16619433 RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY Fusion Pharmaceuticals Inc. CRAIGO, BAHAR ALAWI 1699 Other Non-Final OA 5d Pending Dec 04, 2019
15661272 ENZYMATIC PRE-TREATMENT OF MARKET PULP TO IMPROVE FIBER DRAINAGE AND PHYSICAL PROPERTIES Exzymatic Deinking Technologies, LLC CALANDRA, ANTHONY J 1748 §103 Final Rejection 4d overdue Pending Jul 27, 2017

Managing Pabst Patent Group, LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month